GlaxoSmithKline’s Latest Developments and Valuation

1 2 3 4 5 6 7 8 9
Part 2
GlaxoSmithKline’s Latest Developments and Valuation PART 2 OF 9

GlaxoSmithKline’s Quarterly Revenues

GlaxoSmithKline’s revenues

GlaxoSmithKline (GSK) reported a 12.0% rise in revenues to 7.3 billion pounds in 2Q17 compared to 6.5 billion pounds in 2Q16.

GlaxoSmithKline’s Quarterly Revenues

Interested in ADRU? Don't miss the next report.

Receive e-mail alerts for new research on ADRU

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart shows the revenue trend for GSK over the last few quarters and estimates for 3Q17.

3Q17 revenues

For 3Q17, Wall Street analysts estimate revenue growth of 4.7% to 7.9 billion pounds compared to 7.5 billion pounds in 3Q16.

2Q17 revenues

GlaxoSmithKline’s 12.0% rise in 2Q17 revenues to 7.3 billion pounds compared to 2Q16 includes a 3.0% rise in revenues at constant exchange rates and a 9.0% rise due to the favorable impact of foreign exchange.

Growth in 2Q17 was driven by the strong performance of new pharmaceutical products and vaccines across the United States and outside the US markets. Also, the weakening of the sterling pound against all major currencies in 2Q17 resulted in a positive impact of foreign exchange.

The company reports its business in three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. For 2Q17, all the segments reported positive growth in revenues.

At constant exchange rates, the US markets reported a 5.0% rise in revenues to 2.7 billion pounds. The European markets reported a 2.0% rise in revenues to 2.0 billion pounds, and other international markets reported a 1.0% rise in revenues to 2.6 billion pounds in 2Q17 compared to 2Q16.

The BLDRS Europe Select ADR ETF (ADRU) has 2.9% of its total assets in GlaxoSmithKline (GSK). ADRU also holds 2.6% in Novo Nordisk (NVO), 2.5% in AstraZeneca (AZN), and 3.3% in Sanofi (SNY).


Please select a profession that best describes you: